lazybumbum personal page - To The Moon

lazybumbum

lazybumbum

No personal profile

3Follow

1Followers

0Topic

0Badge

2022-03-23

Insightful

Cathie Wood's ARK Invest Trades for 3/22: Buy Burning Rock Biotech, Sell Vertex

2022-03-05

😊 Happy to be trading on Tiger broker!

2022-03-05

Hurray!

2022-02-12

Ok

2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4104310782063520","uuid":"4104310782063520","gmtCreate":1641208892283,"gmtModify":1646458542270,"name":"lazybumbum","pinyin":"lazybumbum","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.itradeup.com/news/1ab59679b3c9c9cc73f48a1159a6c133","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":3,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9037983107,"gmtCreate":1648005605852,"gmtModify":1676534291961,"author":{"id":"4104310782063520","authorId":"4104310782063520","name":"lazybumbum","avatar":"https://static.itradeup.com/news/1ab59679b3c9c9cc73f48a1159a6c133","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104310782063520","authorIdStr":"4104310782063520"},"themes":[],"htmlText":"Insightful&nbsp;","listText":"Insightful&nbsp;","text":"Insightful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9037983107","repostId":"1173237813","repostType":4,"repost":{"id":"1173237813","kind":"news","pubTimestamp":1647997469,"share":"https://ttm.financial/m/news/1173237813?lang=&edition=fundamental","pubTime":"2022-03-23 09:04","market":"us","language":"en","title":"Cathie Wood's ARK Invest Trades for 3/22: Buy Burning Rock Biotech, Sell Vertex","url":"https://stock-news.laohu8.com/highlight/detail?id=1173237813","media":"24/7 wall street","summary":"Markets gained momentum on Tuesday with the Nasdaq almost hitting a 2% gain on the day.ARK Invest fu","content":"<html><head></head><body><p>Markets gained momentum on Tuesday with the Nasdaq almost hitting a 2% gain on the day.</p><p>ARK Invest funds each saw sizable gains across the board, despite practically no trading action in the actual ETF holdings.</p><p>ARKW performed the best out of the group, with a 4.8% gain on the day, while ARKX did the worst, up 1.8%.</p><p>The ARK Fintech Innovation ETF (NYSEARCA: ARKF) deals mainly with up-and-coming fintech stocks, as the name suggests. Some of its biggest holdings include Square, Zillow, Pinterest, PayPal and Alibaba. Net assets for the fund are currently $2.2 billion. There was one notable trade in this fund: <b>NO TRADES</b></p><p>ARK Genomic Revolution ETF (NYSEARCA: ARKG) looks at companies across multiple industries, but the general focus is on health care and companies that are changing the game technologically in this field. The biggest holdings are Pacific Biosciences, Teladoc Health, CRISPR and Fate Therapeutics. Net assets for the fund are currently $5.1 billion. Here are some notable trades in this fund: Buy 1,974 shares of Adaptive Biotechnologies, Buy 49,999 shares of <a href=\"https://laohu8.com/S/BNR\">Burning Rock Biotech Limited</a> , Sell 13,000 shares of <a href=\"https://laohu8.com/S/VTNR\">Vertex</a> , &amp; Sell 606 shares of Cellectis.</p><p>ARK Innovation ETF (NYSEARCA: ARKK) has a particular focus on disruptive innovation across multiple industries, but primarily tech. Some of the biggest names are in this fund, including Tesla, Roku, Square, Zillow and Spotify. Net assets for this fund are currently $16.2 billion. Here are some notable trades in this fund: <b>NO TRADES</b></p><p>ARK Autonomous Technology &amp; Robotics ETF (NYSEARCA: ARKQ) is focused, unsurprisingly, on companies that are in the field of autonomous technology and robotics, specifically ones that are disruptively innovating. Big names in this fund include Tesla, Alphabet, JD.com, Baidu and Iridium. Net assets for this fund are currently $2.2 billion. Here are some notable trades in the fund: <b>NO TRADES</b></p><p>ARK Next Generation Internet ETF (NYSEARCA: ARKW) is focused on companies that are disruptively innovating within the theme of the next generation of the internet. Some names in this fund are similar to the others, including Tesla, Square, Grayscale Bitcoin Trust, Facebook and Snap. Net assets for this fund are currently $3.8 billion. Here are the notable trades in the fund: <b>NO TRADES</b></p><p>Ark Space Exploration &amp; Innovation ETF (NYSEARCA: ARKX) is focused primarily on companies developing technology around spaceflight. Big names in this fund include Trimble, Kratos, Nvidia, Amazon and Iridium. Net assets for this fund are currently $468.9 million. There was one notable purchase in the fund: <b>NO TRADES</b></p><p>Check out all the trades here:</p><p><img src=\"https://static.tigerbbs.com/f9a1a3881c90c76ab93c416c7df28f97\" tg-width=\"930\" tg-height=\"315\" referrerpolicy=\"no-referrer\"/></p></body></html>","source":"lsy1620372341666","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood's ARK Invest Trades for 3/22: Buy Burning Rock Biotech, Sell Vertex</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood's ARK Invest Trades for 3/22: Buy Burning Rock Biotech, Sell Vertex\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-23 09:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://247wallst.com/investing/2022/03/22/cathie-woods-ark-invest-trades-for-3-22/><strong>24/7 wall street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Markets gained momentum on Tuesday with the Nasdaq almost hitting a 2% gain on the day.ARK Invest funds each saw sizable gains across the board, despite practically no trading action in the actual ETF...</p>\n\n<a href=\"https://247wallst.com/investing/2022/03/22/cathie-woods-ark-invest-trades-for-3-22/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKG":"ARK Genomic Revolution ETF","VTNR":"顶点能源","BNR":"燃石医学","ARKK":"ARK Innovation ETF","ARKF":"ARK Fintech Innovation ETF"},"source_url":"https://247wallst.com/investing/2022/03/22/cathie-woods-ark-invest-trades-for-3-22/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173237813","content_text":"Markets gained momentum on Tuesday with the Nasdaq almost hitting a 2% gain on the day.ARK Invest funds each saw sizable gains across the board, despite practically no trading action in the actual ETF holdings.ARKW performed the best out of the group, with a 4.8% gain on the day, while ARKX did the worst, up 1.8%.The ARK Fintech Innovation ETF (NYSEARCA: ARKF) deals mainly with up-and-coming fintech stocks, as the name suggests. Some of its biggest holdings include Square, Zillow, Pinterest, PayPal and Alibaba. Net assets for the fund are currently $2.2 billion. There was one notable trade in this fund: NO TRADESARK Genomic Revolution ETF (NYSEARCA: ARKG) looks at companies across multiple industries, but the general focus is on health care and companies that are changing the game technologically in this field. The biggest holdings are Pacific Biosciences, Teladoc Health, CRISPR and Fate Therapeutics. Net assets for the fund are currently $5.1 billion. Here are some notable trades in this fund: Buy 1,974 shares of Adaptive Biotechnologies, Buy 49,999 shares of Burning Rock Biotech Limited , Sell 13,000 shares of Vertex , & Sell 606 shares of Cellectis.ARK Innovation ETF (NYSEARCA: ARKK) has a particular focus on disruptive innovation across multiple industries, but primarily tech. Some of the biggest names are in this fund, including Tesla, Roku, Square, Zillow and Spotify. Net assets for this fund are currently $16.2 billion. Here are some notable trades in this fund: NO TRADESARK Autonomous Technology & Robotics ETF (NYSEARCA: ARKQ) is focused, unsurprisingly, on companies that are in the field of autonomous technology and robotics, specifically ones that are disruptively innovating. Big names in this fund include Tesla, Alphabet, JD.com, Baidu and Iridium. Net assets for this fund are currently $2.2 billion. Here are some notable trades in the fund: NO TRADESARK Next Generation Internet ETF (NYSEARCA: ARKW) is focused on companies that are disruptively innovating within the theme of the next generation of the internet. Some names in this fund are similar to the others, including Tesla, Square, Grayscale Bitcoin Trust, Facebook and Snap. Net assets for this fund are currently $3.8 billion. Here are the notable trades in the fund: NO TRADESArk Space Exploration & Innovation ETF (NYSEARCA: ARKX) is focused primarily on companies developing technology around spaceflight. Big names in this fund include Trimble, Kratos, Nvidia, Amazon and Iridium. Net assets for this fund are currently $468.9 million. There was one notable purchase in the fund: NO TRADESCheck out all the trades here:","news_type":1},"isVote":1,"tweetType":1,"viewCount":318,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9031195342,"gmtCreate":1646455999329,"gmtModify":1676534132200,"author":{"id":"4104310782063520","authorId":"4104310782063520","name":"lazybumbum","avatar":"https://static.itradeup.com/news/1ab59679b3c9c9cc73f48a1159a6c133","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104310782063520","authorIdStr":"4104310782063520"},"themes":[],"htmlText":"😊 Happy to be trading on Tiger broker!","listText":"😊 Happy to be trading on Tiger broker!","text":"😊 Happy to be trading on Tiger broker!","images":[{"img":"https://static.itradeup.com/news/35040e2d23b87db7cf27b472d1363d32","width":"1080","height":"1450"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9031195342","isVote":1,"tweetType":1,"viewCount":617,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9031195029,"gmtCreate":1646455885074,"gmtModify":1676534132205,"author":{"id":"4104310782063520","authorId":"4104310782063520","name":"lazybumbum","avatar":"https://static.itradeup.com/news/1ab59679b3c9c9cc73f48a1159a6c133","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104310782063520","authorIdStr":"4104310782063520"},"themes":[],"htmlText":"Hurray!","listText":"Hurray!","text":"Hurray!","images":[{"img":"https://static.itradeup.com/news/35040e2d23b87db7cf27b472d1363d32","width":"1080","height":"1450"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9031195029","isVote":1,"tweetType":1,"viewCount":576,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9092877863,"gmtCreate":1644595236458,"gmtModify":1676533944939,"author":{"id":"4104310782063520","authorId":"4104310782063520","name":"lazybumbum","avatar":"https://static.itradeup.com/news/1ab59679b3c9c9cc73f48a1159a6c133","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104310782063520","authorIdStr":"4104310782063520"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092877863","repostId":"2210159258","repostType":4,"repost":{"id":"2210159258","kind":"highlight","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4512":"苹果概念","GILD":"吉利德科学","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","MMM":"3M","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"tweetType":1,"viewCount":674,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9092877863,"gmtCreate":1644595236458,"gmtModify":1676533944939,"author":{"id":"4104310782063520","authorId":"4104310782063520","name":"lazybumbum","avatar":"https://static.itradeup.com/news/1ab59679b3c9c9cc73f48a1159a6c133","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104310782063520","authorIdStr":"4104310782063520"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092877863","repostId":"2210159258","repostType":4,"repost":{"id":"2210159258","kind":"highlight","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4512":"苹果概念","GILD":"吉利德科学","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","MMM":"3M","BK4139":"生物科技"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"tweetType":1,"viewCount":674,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9037983107,"gmtCreate":1648005605852,"gmtModify":1676534291961,"author":{"id":"4104310782063520","authorId":"4104310782063520","name":"lazybumbum","avatar":"https://static.itradeup.com/news/1ab59679b3c9c9cc73f48a1159a6c133","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104310782063520","authorIdStr":"4104310782063520"},"themes":[],"htmlText":"Insightful&nbsp;","listText":"Insightful&nbsp;","text":"Insightful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9037983107","repostId":"1173237813","repostType":4,"repost":{"id":"1173237813","kind":"news","pubTimestamp":1647997469,"share":"https://ttm.financial/m/news/1173237813?lang=&edition=fundamental","pubTime":"2022-03-23 09:04","market":"us","language":"en","title":"Cathie Wood's ARK Invest Trades for 3/22: Buy Burning Rock Biotech, Sell Vertex","url":"https://stock-news.laohu8.com/highlight/detail?id=1173237813","media":"24/7 wall street","summary":"Markets gained momentum on Tuesday with the Nasdaq almost hitting a 2% gain on the day.ARK Invest fu","content":"<html><head></head><body><p>Markets gained momentum on Tuesday with the Nasdaq almost hitting a 2% gain on the day.</p><p>ARK Invest funds each saw sizable gains across the board, despite practically no trading action in the actual ETF holdings.</p><p>ARKW performed the best out of the group, with a 4.8% gain on the day, while ARKX did the worst, up 1.8%.</p><p>The ARK Fintech Innovation ETF (NYSEARCA: ARKF) deals mainly with up-and-coming fintech stocks, as the name suggests. Some of its biggest holdings include Square, Zillow, Pinterest, PayPal and Alibaba. Net assets for the fund are currently $2.2 billion. There was one notable trade in this fund: <b>NO TRADES</b></p><p>ARK Genomic Revolution ETF (NYSEARCA: ARKG) looks at companies across multiple industries, but the general focus is on health care and companies that are changing the game technologically in this field. The biggest holdings are Pacific Biosciences, Teladoc Health, CRISPR and Fate Therapeutics. Net assets for the fund are currently $5.1 billion. Here are some notable trades in this fund: Buy 1,974 shares of Adaptive Biotechnologies, Buy 49,999 shares of <a href=\"https://laohu8.com/S/BNR\">Burning Rock Biotech Limited</a> , Sell 13,000 shares of <a href=\"https://laohu8.com/S/VTNR\">Vertex</a> , &amp; Sell 606 shares of Cellectis.</p><p>ARK Innovation ETF (NYSEARCA: ARKK) has a particular focus on disruptive innovation across multiple industries, but primarily tech. Some of the biggest names are in this fund, including Tesla, Roku, Square, Zillow and Spotify. Net assets for this fund are currently $16.2 billion. Here are some notable trades in this fund: <b>NO TRADES</b></p><p>ARK Autonomous Technology &amp; Robotics ETF (NYSEARCA: ARKQ) is focused, unsurprisingly, on companies that are in the field of autonomous technology and robotics, specifically ones that are disruptively innovating. Big names in this fund include Tesla, Alphabet, JD.com, Baidu and Iridium. Net assets for this fund are currently $2.2 billion. Here are some notable trades in the fund: <b>NO TRADES</b></p><p>ARK Next Generation Internet ETF (NYSEARCA: ARKW) is focused on companies that are disruptively innovating within the theme of the next generation of the internet. Some names in this fund are similar to the others, including Tesla, Square, Grayscale Bitcoin Trust, Facebook and Snap. Net assets for this fund are currently $3.8 billion. Here are the notable trades in the fund: <b>NO TRADES</b></p><p>Ark Space Exploration &amp; Innovation ETF (NYSEARCA: ARKX) is focused primarily on companies developing technology around spaceflight. Big names in this fund include Trimble, Kratos, Nvidia, Amazon and Iridium. Net assets for this fund are currently $468.9 million. There was one notable purchase in the fund: <b>NO TRADES</b></p><p>Check out all the trades here:</p><p><img src=\"https://static.tigerbbs.com/f9a1a3881c90c76ab93c416c7df28f97\" tg-width=\"930\" tg-height=\"315\" referrerpolicy=\"no-referrer\"/></p></body></html>","source":"lsy1620372341666","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood's ARK Invest Trades for 3/22: Buy Burning Rock Biotech, Sell Vertex</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood's ARK Invest Trades for 3/22: Buy Burning Rock Biotech, Sell Vertex\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-23 09:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://247wallst.com/investing/2022/03/22/cathie-woods-ark-invest-trades-for-3-22/><strong>24/7 wall street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Markets gained momentum on Tuesday with the Nasdaq almost hitting a 2% gain on the day.ARK Invest funds each saw sizable gains across the board, despite practically no trading action in the actual ETF...</p>\n\n<a href=\"https://247wallst.com/investing/2022/03/22/cathie-woods-ark-invest-trades-for-3-22/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKG":"ARK Genomic Revolution ETF","VTNR":"顶点能源","BNR":"燃石医学","ARKK":"ARK Innovation ETF","ARKF":"ARK Fintech Innovation ETF"},"source_url":"https://247wallst.com/investing/2022/03/22/cathie-woods-ark-invest-trades-for-3-22/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173237813","content_text":"Markets gained momentum on Tuesday with the Nasdaq almost hitting a 2% gain on the day.ARK Invest funds each saw sizable gains across the board, despite practically no trading action in the actual ETF holdings.ARKW performed the best out of the group, with a 4.8% gain on the day, while ARKX did the worst, up 1.8%.The ARK Fintech Innovation ETF (NYSEARCA: ARKF) deals mainly with up-and-coming fintech stocks, as the name suggests. Some of its biggest holdings include Square, Zillow, Pinterest, PayPal and Alibaba. Net assets for the fund are currently $2.2 billion. There was one notable trade in this fund: NO TRADESARK Genomic Revolution ETF (NYSEARCA: ARKG) looks at companies across multiple industries, but the general focus is on health care and companies that are changing the game technologically in this field. The biggest holdings are Pacific Biosciences, Teladoc Health, CRISPR and Fate Therapeutics. Net assets for the fund are currently $5.1 billion. Here are some notable trades in this fund: Buy 1,974 shares of Adaptive Biotechnologies, Buy 49,999 shares of Burning Rock Biotech Limited , Sell 13,000 shares of Vertex , & Sell 606 shares of Cellectis.ARK Innovation ETF (NYSEARCA: ARKK) has a particular focus on disruptive innovation across multiple industries, but primarily tech. Some of the biggest names are in this fund, including Tesla, Roku, Square, Zillow and Spotify. Net assets for this fund are currently $16.2 billion. Here are some notable trades in this fund: NO TRADESARK Autonomous Technology & Robotics ETF (NYSEARCA: ARKQ) is focused, unsurprisingly, on companies that are in the field of autonomous technology and robotics, specifically ones that are disruptively innovating. Big names in this fund include Tesla, Alphabet, JD.com, Baidu and Iridium. Net assets for this fund are currently $2.2 billion. Here are some notable trades in the fund: NO TRADESARK Next Generation Internet ETF (NYSEARCA: ARKW) is focused on companies that are disruptively innovating within the theme of the next generation of the internet. Some names in this fund are similar to the others, including Tesla, Square, Grayscale Bitcoin Trust, Facebook and Snap. Net assets for this fund are currently $3.8 billion. Here are the notable trades in the fund: NO TRADESArk Space Exploration & Innovation ETF (NYSEARCA: ARKX) is focused primarily on companies developing technology around spaceflight. Big names in this fund include Trimble, Kratos, Nvidia, Amazon and Iridium. Net assets for this fund are currently $468.9 million. There was one notable purchase in the fund: NO TRADESCheck out all the trades here:","news_type":1},"isVote":1,"tweetType":1,"viewCount":318,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9031195342,"gmtCreate":1646455999329,"gmtModify":1676534132200,"author":{"id":"4104310782063520","authorId":"4104310782063520","name":"lazybumbum","avatar":"https://static.itradeup.com/news/1ab59679b3c9c9cc73f48a1159a6c133","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104310782063520","authorIdStr":"4104310782063520"},"themes":[],"htmlText":"😊 Happy to be trading on Tiger broker!","listText":"😊 Happy to be trading on Tiger broker!","text":"😊 Happy to be trading on Tiger broker!","images":[{"img":"https://static.itradeup.com/news/35040e2d23b87db7cf27b472d1363d32","width":"1080","height":"1450"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9031195342","isVote":1,"tweetType":1,"viewCount":617,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9031195029,"gmtCreate":1646455885074,"gmtModify":1676534132205,"author":{"id":"4104310782063520","authorId":"4104310782063520","name":"lazybumbum","avatar":"https://static.itradeup.com/news/1ab59679b3c9c9cc73f48a1159a6c133","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104310782063520","authorIdStr":"4104310782063520"},"themes":[],"htmlText":"Hurray!","listText":"Hurray!","text":"Hurray!","images":[{"img":"https://static.itradeup.com/news/35040e2d23b87db7cf27b472d1363d32","width":"1080","height":"1450"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9031195029","isVote":1,"tweetType":1,"viewCount":576,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}